Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q581334> ?p ?o }
Showing triples 1 to 36 of
36
with 100 triples per page.
- Q581334 subject Q8790412.
- Q581334 subject Q9536267.
- Q581334 abstract "The combination preparation fluticasone/salmeterol is a formulation containing fluticasone propionate and salmeterol xinafoate, used in the management of asthma and chronic obstructive pulmonary disease (COPD). It is marketed by GlaxoSmithKline under various trade names including Advair (in the US and Canada), Seretide (Brazil, India, Australia, Colombia, EU, México, New Zealand, South Africa, South Korea, Turkey, UK, Estonia), Viani (Germany), Adoair (Japan) and Foxair (South Africa). In India it is marketed by Intas under the trade name 'Quikhale SF'. Annual worldwide sales were approximately US$7 billion in 2009. Patent protection in the US expired in 2010, and European patent protection expired in 2013. However, the availability of a generic form of Advair in the United States may be significantly delayed because the Food and Drug Administration has not determined a standard for the bioequivalence of inhaled steroids in multi-dose inhalers or dry powder inhalers.Fluticasone, a corticosteroid, is the anti-inflammatory component of the combination, while salmeterol treats constriction of the airways. Together, they help prevent symptoms of coughing, wheezing and shortness of breath.".
- Q581334 atcPrefix "R03".
- Q581334 atcSuffix "AK06".
- Q581334 pubchem "9811567".
- Q581334 thumbnail Fluticasone-salmeterol2DCSD.svg?width=300.
- Q581334 wikiPageWikiLink Q1002165.
- Q581334 wikiPageWikiLink Q1044248.
- Q581334 wikiPageWikiLink Q1334805.
- Q581334 wikiPageWikiLink Q1645498.
- Q581334 wikiPageWikiLink Q16897784.
- Q581334 wikiPageWikiLink Q1755275.
- Q581334 wikiPageWikiLink Q199804.
- Q581334 wikiPageWikiLink Q210420.
- Q581334 wikiPageWikiLink Q212322.
- Q581334 wikiPageWikiLink Q3327495.
- Q581334 wikiPageWikiLink Q35869.
- Q581334 wikiPageWikiLink Q422549.
- Q581334 wikiPageWikiLink Q424333.
- Q581334 wikiPageWikiLink Q6671832.
- Q581334 wikiPageWikiLink Q8564098.
- Q581334 wikiPageWikiLink Q8790412.
- Q581334 wikiPageWikiLink Q898750.
- Q581334 wikiPageWikiLink Q9536267.
- Q581334 atcPrefix "R03".
- Q581334 atcSuffix "AK06".
- Q581334 pubchem "9811567".
- Q581334 type ChemicalSubstance.
- Q581334 type Drug.
- Q581334 type ChemicalObject.
- Q581334 type Thing.
- Q581334 type Q8386.
- Q581334 comment "The combination preparation fluticasone/salmeterol is a formulation containing fluticasone propionate and salmeterol xinafoate, used in the management of asthma and chronic obstructive pulmonary disease (COPD). It is marketed by GlaxoSmithKline under various trade names including Advair (in the US and Canada), Seretide (Brazil, India, Australia, Colombia, EU, México, New Zealand, South Africa, South Korea, Turkey, UK, Estonia), Viani (Germany), Adoair (Japan) and Foxair (South Africa).".
- Q581334 label "Fluticasone/salmeterol".
- Q581334 depiction Fluticasone-salmeterol2DCSD.svg.